Marc Carrier: Proud to Share the Results of the WAVe Study
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn:
”Proud to share the results of the WAVe Study published in AjHematology
In this Canadian multicenter collaboration across six academic centers, we evaluated weight-adjusted dalteparin dosing (up to 33,000 IU/day) in patients with cancer-associated thrombosis weighing >90 kg.
Despite early study termination due to recruitment challenges — following the rapid uptake of DOACs for VTE and updated ISTH guidance removing the upper weight limit for DOAC use — our findings remain clinically relevant:
- Major bleeding: 5.3% at 30 days
- Recurrent VTE: 1.2% at 30 days
- No significant drug accumulation (based on anti-Xa levels)
These results suggest that weight-adjusted LMWH remains a safe and effective option for selected patients with cancer and obesity, particularly those at higher bleeding risk or with contraindications to DOACs.”
Read the full article here.
Article: A Multicenter Prospective Cohort Study on the Use of Weight-Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism—The WAVe Study
Authors: Tzu-Fei Wang, Erik Yeo, Peter L. Gross, Chantal Séguin, Cynthia Wu, Sudeep Shivakumar, Ranjeeta Mallick, Aurélien Delluc, Julien D’Astous, Miriam Kimpton, Guillaume Roberge, Deborah M. Siegal, Tobias Tritschler, Grégoire Le Gal, Marc Carrier
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
-
Jan 9, 2026, 06:12James Caldwell on The Hidden Culprit in Perimesencephalic SAH